Search

Your search keyword '"Claes, Kathleen B M"' showing total 338 results

Search Constraints

Start Over You searched for: Author "Claes, Kathleen B M" Remove constraint Author: "Claes, Kathleen B M"
338 results on '"Claes, Kathleen B M"'

Search Results

3. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

4. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

7. Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus

8. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

9. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk

11. Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype–phenotype correlation

13. Publisher Correction: Shared heritability and functional enrichment across six solid cancers

15. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

16. Shared heritability and functional enrichment across six solid cancers

18. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

19. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

20. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3

21. The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

22. Correction: Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype–phenotype correlation

23. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers

24. Belgian guidelines for the frequency of participation of the Medical Centers of Human Genetics to External Quality Assessment schemes for analyses focused on rare diseases

25. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

26. Clinical, splicing, and functional analysis to classify BRCA2 exon 3 variants:Application of a points-based ACMG/AMP approach

27. Clinical, splicing, and functional analysis to classify BRCA2 exon 3 variants: Application of a points-based ACMG/AMP approach

28. TIM3+ TRBV11-2 T cells and IFNγ signature in patrolling monocytes and CD16+ NK cells delineate MIS-C

29. Prevalence of Germline Pathogenic Variants in Cancer Predisposing Genes in Czech and Belgian Pancreatic Cancer Patients

31. Author Correction : A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

32. Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1

33. Characterization of the cancer spectrum in men with germline BRCA1 and BRCA2 pathogenic variants

34. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

35. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

36. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

37. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

38. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families

39. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

40. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

42. Chromosomal radiosensitivity of triple negative breast cancer patients

43. The FANCM :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

44. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study

45. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

46. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

47. Thec. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant : breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium

48. A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk

49. Clinical spectrum of individuals with pathogenicN F1missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype–phenotype study in neurofibromatosis type 1

Catalog

Books, media, physical & digital resources